表皮水疱症治療薬の世界市場

表皮水疱症治療薬の世界市場は2030年までに81億米ドルに達する見込み

2023年に41億米ドルと推定される表皮水疱症治療薬の世界市場は、分析期間2023-2030年にCAGR 10.2%で成長し、2030年には81億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗生物質は、CAGR 9.3%を記録し、分析期間終了時には40億米ドルに達すると予想されます。鎮痛剤セグメントの成長率は、分析期間中CAGR 10.3％と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 8.6％で成長予測

米国の表皮水疱症治療薬市場は2023年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.9%と9.7%と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界の表皮水疱症治療薬市場- 主要動向と促進要因まとめ

表皮水疱症（EB）はまれな遺伝性結合組織障害であり、その結果、皮膚は極めて脆弱になり、些細な摩擦や外傷で水ぶくれができたり裂けたりしやすくなります。EBの重症度は様々で、生命を脅かすものもあります。現在の治療法は、主に症状の管理と感染症や慢性創傷などの合併症の予防に重点を置いています。従来の治療法には、創傷ケア、疼痛管理、栄養サポート、感染症対策などがあります。しかし、最近の遺伝子治療、蛋白補充療法、幹細胞治療などの進歩は、より効果的で的を絞った治療のための有望な新しい道を提供しています。研究者や製薬会社は、EBの根本的な遺伝的原因に対処するため、こうした革新的なアプローチを積極的に模索しており、患者のQOLの大幅な向上を目指しています。

表皮水疱症治療薬市場は、技術の進歩や疾患の遺伝的基盤のより深い理解に牽引され、著しい発展を遂げています。大きな動向の一つは、EBの原因となる遺伝子変異を修正する可能性を示したCRISPR-Cas9などの遺伝子編集技術への注目が高まっていることです。さらに、EB患者の欠損または機能不全に陥ったタンパク質を回復させることを目的としたタンパク質補充療法も支持を集めています。幹細胞療法はもう一つの有望なフロンティアであり、健康な皮膚組織を再生するために幹細胞を使用する臨床試験が行われています。さらに、個々の患者の特定の遺伝子変異や特徴に合わせて治療を行う個別化医療への動向も高まっています。このアプローチは、治療効果を高めるだけでなく、潜在的な副作用を最小限に抑えることもできます。

表皮水疱症治療薬市場の成長は、いくつかの要因によって牽引されています。遺伝子治療、タンパク質補充療法、幹細胞治療における技術的進歩は、EBに利用可能な治療の選択肢を拡大し、それによって市場の成長を促進しています。また、EBの有病率の上昇は、認知度の向上や早期診断と相まって、効果的な治療法の需要拡大に寄与しています。さらに、製薬会社や学術機関による研究開発への多額の投資が技術革新を促進し、新たな治療法の開発を加速させています。希少疾病用医薬品の指定や迅速承認などの規制上の支援も、EB療法の開発を後押ししています。さらに、個別化医療アプローチの採用が増加しており、ターゲットを絞った個別化治療への需要が高まっています。最後に、患者支援団体や公衆衛生への取り組みが、認知度の向上や新治療法の採用促進に重要な役割を果たしており、最終的に市場の拡大に寄与しています。

調査対象企業の例（注目の86社）

• Abeona Therapeutics
• Aegle Therapeutics
• Alphyn Biologics
• Castle Creek Biosciences, Inc.
• Chiesi Global Rare Disease
• Eloxx Pharmaceuticals Inc
• Holostem Terapie Avanzate Srl
• InMed Pharmaceuticals Inc.
• Krystal Biotech
• Prime Therapeutics
• Quoin Pharmaceuticals
• RegeneRx Biopharmaceuticals, Inc.
• RHEACELL
• Shionogi & Co., Ltd.
• TWI Biotechnology, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Epidermolysis Bullosa Therapeutics Market to Reach US$8.1 Billion by 2030

The global market for Epidermolysis Bullosa Therapeutics estimated at US$4.1 Billion in the year 2023, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 10.2% over the analysis period 2023-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Analgesics segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 8.6% CAGR

The Epidermolysis Bullosa Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 9.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Epidermolysis Bullosa Therapeutics Market - Key Trends and Drivers Summarized

Epidermolysis Bullosa (EB) is a rare, inherited connective tissue disorder that results in the skin being extremely fragile and prone to blistering and tearing from minor friction or trauma. The severity of EB can vary widely, with some forms being life-threatening. Current therapeutic approaches primarily focus on managing symptoms and preventing complications, such as infections and chronic wounds. Traditional treatments include wound care, pain management, nutritional support, and infection control. However, recent advancements in gene therapy, protein replacement therapy, and stem cell therapy offer promising new avenues for more effective and targeted treatments. Researchers and pharmaceutical companies are actively exploring these innovative approaches to address the underlying genetic causes of EB, aiming to improve the quality of life for patients significantly.

The market for Epidermolysis Bullosa therapeutics has been witnessing significant developments driven by technological advancements and a deeper understanding of the disease's genetic basis. One of the major trends is the increasing focus on gene editing technologies, such as CRISPR-Cas9, which have shown potential in correcting genetic mutations responsible for EB. Additionally, protein replacement therapies, which aim to restore the missing or dysfunctional proteins in EB patients, are also gaining traction. Stem cell therapy represents another promising frontier, with clinical trials exploring the use of stem cells to regenerate healthy skin tissue. Furthermore, there is a growing trend towards personalized medicine, where treatments are tailored to the specific genetic mutations and characteristics of individual patients. This approach not only enhances treatment efficacy but also minimizes potential side effects.

The growth in the Epidermolysis Bullosa therapeutics market is driven by several factors. Technological advancements in gene therapy, protein replacement therapy, and stem cell therapy are expanding the treatment options available for EB, thereby driving market growth. The rising prevalence of EB, coupled with increased awareness and early diagnosis, is also contributing to the growing demand for effective therapies. Additionally, substantial investments in research and development by pharmaceutical companies and academic institutions are fostering innovation and accelerating the development of new treatments. Regulatory support, including orphan drug designations and fast-track approvals, is encouraging the development of EB therapies. Furthermore, the increasing adoption of personalized medicine approaches is generating demand for targeted and individualized treatments. Lastly, patient advocacy groups and public health initiatives are playing a crucial role in raising awareness and driving the adoption of new therapies, ultimately contributing to the market's expansion.

Select Competitors (Total 86 Featured) -

• Abeona Therapeutics
• Aegle Therapeutics
• Alphyn Biologics
• Castle Creek Biosciences, Inc.
• Chiesi Global Rare Disease
• Eloxx Pharmaceuticals Inc
• Holostem Terapie Avanzate Srl
• InMed Pharmaceuticals Inc.
• Krystal Biotech
• Prime Therapeutics
• Quoin Pharmaceuticals
• RegeneRx Biopharmaceuticals, Inc.
• RHEACELL
• Shionogi & Co., Ltd.
• TWI Biotechnology, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Epidermolysis Bullosa Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Epidermolysis Bullosa Expands Addressable Market Opportunity
  • Advancements in Gene Therapy Propel Growth in Epidermolysis Bullosa Therapeutics Market
  • Innovative Protein Replacement Therapies Strengthen Business Case for EB Treatments
  • Stem Cell Therapy Developments Accelerate Demand for Novel EB Therapeutics
  • Increasing Awareness and Early Diagnosis Spur Growth in EB Therapeutics Market
  • Integration of Digital Health Technologies Throws the Spotlight on EB Treatment Advancements
  • Growing Use of CRISPR-Cas9 Technology Expands Addressable Market for EB Treatments
  • Emerging Combination Therapies Propel Growth in Epidermolysis Bullosa Market
  • Economic Burden of EB on Patients and Healthcare Systems Drives Demand for Cost-Effective Therapies
  • Increasing Healthcare Expenditure Accelerates Demand for Epidermolysis Bullosa Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Epidermolysis Bullosa Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Epidermolysis Bullosa Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• JAPAN
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• CHINA
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• EUROPE
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Epidermolysis Bullosa Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• FRANCE
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• GERMANY
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Rest of Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Asia-Pacific 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of World 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030

IV. COMPETITION